Rosetta Genomics Posts Q3 Revenues of $136K, Seeks $2.5M in Private Placement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported third-quarter revenues of $136,000, compared to no revenues for the comparable period of 2009.

The Rehovot, Israel-based developer of microRNA-based diagnostic products has three tests on the market and is preparing to launch next-generation versions of those tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.